{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T06:43:34Z","timestamp":1775889814559,"version":"3.50.1"},"reference-count":268,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T00:00:00Z","timestamp":1611446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T00:00:00Z","timestamp":1611446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s40262-020-00981-0","type":"journal-article","created":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T16:02:27Z","timestamp":1611504147000},"page":"409-445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions"],"prefix":"10.1007","volume":"60","author":[{"given":"Sophie","family":"Magr\u00e9ault","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3113-7301","authenticated-orcid":false,"given":"Manon","family":"Launay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Sermet-Gaudelus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5971-6316","authenticated-orcid":false,"given":"Vincent","family":"Jullien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,24]]},"reference":[{"key":"981_CR1","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","volume":"373","author":"BP O\u2019Sullivan","year":"2009","unstructured":"O\u2019Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373:1891\u2013904.","journal-title":"Lancet"},{"key":"981_CR2","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1183\/09031936.96.09020334","volume":"9","author":"RK Brown","year":"1996","unstructured":"Brown RK, Wyatt H, Price JF, Kelly FJ. Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress. Eur Respir J. 1996;9:334\u20139.","journal-title":"Eur Respir J."},{"key":"981_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2165\/00003088-199324060-00005","volume":"24","author":"CA Lindsay","year":"1993","unstructured":"Lindsay CA, Bosso JA. Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations. Clin Pharmacokinet. 1993;24:496\u2013506.","journal-title":"Clin Pharmacokinet."},{"key":"981_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/jac\/27.3.285","volume":"27","author":"N Bolister","year":"1991","unstructured":"Bolister N, Basker M, Hodges NA, Marriott C. The diffusion of beta-lactam antibiotics through mixed gels of cystic fibrosis-derived mucin and Pseudomonas aeruginosa alginate. J Antimicrob Chemother. 1991;27:285\u201393.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.addr.2014.11.017","volume":"85","author":"O Ciofu","year":"2015","unstructured":"Ciofu O, Tolker-Nielsen T, Jensen P\u00d8, Wang H, H\u00f8iby N. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. Adv Drug Deliv Rev. 2015;85:7\u201323.","journal-title":"Adv Drug Deliv Rev."},{"key":"981_CR6","first-page":"761","volume":"132","author":"PM Mendelman","year":"1985","unstructured":"Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis. 1985;132:761\u20135.","journal-title":"Am Rev Respir Dis."},{"key":"981_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/JB.00307-19","volume":"201","author":"PS Stewart","year":"2019","unstructured":"Stewart PS, White B, Boegli L, Hamerly T, Williamson KS, Franklin MJ, et al. Conceptual model of biofilm antibiotic tolerance that integrates phenomena of diffusion, metabolism, gene expression, and physiology. J Bacteriol. 2019;201:1\u201324.","journal-title":"J Bacteriol."},{"key":"981_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/2049-632X.12120","volume":"70","author":"P\u00d8 Jensen","year":"2014","unstructured":"Jensen P\u00d8, Briales A, Brochmann RP, Wang H, Kragh KN, Kolpen M, et al. Formation of hydroxyl radicals contributes to the bactericidal activity of ciprofloxacin against Pseudomonas aeruginosa biofilms. Pathog Dis. 2014;70:440\u20133.","journal-title":"Pathog Dis."},{"key":"981_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/j.1462-5822.2008.01271.x","volume":"11","author":"G D\u00f6ring","year":"2009","unstructured":"D\u00f6ring G, Gulbins E. Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease. Cell Microbiol. 2009;11:208\u201316.","journal-title":"Cell Microbiol."},{"key":"981_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/clinids\/11.3.361","volume":"11","author":"I Brook","year":"1989","unstructured":"Brook I. Inoculum effect. Rev Infect Dis. 1989;11:361\u20138.","journal-title":"Rev Infect Dis."},{"key":"981_CR11","first-page":"615","volume":"27","author":"JL Kuti","year":"2016","unstructured":"Kuti JL. Optimizing antimicrobial pharmacodynamics: a guide for your stewardship program. Rev M\u00e9d Cl\u00edn Las Condes. 2016;27:615\u201324.","journal-title":"Rev M\u00e9d Cl\u00edn Las Condes."},{"key":"981_CR12","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0022-3476(84)80317-0","volume":"105","author":"M Spino","year":"1984","unstructured":"Spino M, Chai RP, Isles AF, Thiessen JJ, Tesoro A, Gold R, et al. Cloxacillin absorption and disposition in cystic fibrosis. J Pediatr. 1984;105:829\u201335.","journal-title":"J Pediatr."},{"key":"981_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/clpt.1990.11","volume":"47","author":"R de Groot","year":"1990","unstructured":"de Groot R, Hack BD, Weber A, Chaffin D, Ramsey B, Smith AL. Pharmacokinetics of ticarcillin in patients with cystic fibrosis: a controlled prospective study. Clin Pharmacol Ther. 1990;47:73\u20138.","journal-title":"Clin Pharmacol Ther."},{"key":"981_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/clpt.1993.150","volume":"54","author":"JP Wang","year":"1993","unstructured":"Wang JP, Unadkat JD, Al-Habet SM, O\u2019Sullivan TA, Williams-Warren J, Smith AL, et al. Disposition of drugs in cystic fibrosis. IV. Mechanisms for enhanced renal clearance of ticarcillin. Clin Pharmacol Ther. 1993;54:293\u2013302.","journal-title":"Clin Pharmacol Ther."},{"key":"981_CR15","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/jac\/30.6.875","volume":"30","author":"L Corvaia","year":"1992","unstructured":"Corvaia L, Li SC, Ioannides-Demos LL, Bowes G, Spicer WJ, Spelman DW, et al. A prospective study of the effects of oral probenecid on the pharmacokinetics of intravenous ticarcillin in patients with cystic fibrosis. J Antimicrob Chemother. 1992;30:875\u20138.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/BF01647752","volume":"15","author":"JP Guggenbichler","year":"1987","unstructured":"Guggenbichler JP, Schneeberger J. Antimicrobial chemotherapy in patients with cystic fibrosis. Infection. 1987;15:397\u2013402.","journal-title":"Infection"},{"key":"981_CR17","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0022-3476(85)80258-4","volume":"106","author":"RF Jacobs","year":"1985","unstructured":"Jacobs RF, Trang JM, Kearns GL, Warren RH, Brown AL, Underwood FL, et al. Ticarcillin\/clavulanic acid pharmacokinetics in children and young adults with cystic fibrosis. J Pediatr. 1985;106:1001\u20137.","journal-title":"J Pediatr."},{"key":"981_CR18","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/j.clinthera.2011.09.010","volume":"33","author":"JT Zobell","year":"2011","unstructured":"Zobell JT, Stockmann C, Young DC, Cash J, McDowell BJ, Korgenski K, et al. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. Clin Ther. 2011;33:1844\u201350.","journal-title":"Clin Ther."},{"key":"981_CR19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1128\/AAC.47.2.541-547.2003","volume":"47","author":"AA Vinks","year":"2003","unstructured":"Vinks AA, Den Hollander JG, Overbeek SE, Jelliffe RW, Mouton JW. Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. Antimicrob Agents Chemother. 2003;47:541\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/jac\/dkt300","volume":"69","author":"JM Butterfield","year":"2014","unstructured":"Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin\/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations. J Antimicrob Chemother. 2014;69:176\u20139.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR21","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1128\/AAC.01477-06","volume":"51","author":"JB Bulitta","year":"2007","unstructured":"Bulitta JB, Duffull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano GL, et al. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother. 2007;51:2497\u2013507.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR22","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1128\/AAC.00296-09","volume":"54","author":"N Patel","year":"2010","unstructured":"Patel N, Scheetz MH, Drusano GL, Lodise TP. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin\u2013tazobactam dosing regimens in hospitalized patients. Antimicrob Agents Chemother. 2010;54:460\u20135.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR23","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1128\/AAC.00521-12","volume":"56","author":"TW Felton","year":"2012","unstructured":"Felton TW, Hope WW, Lomaestro BM, Butterfield JM, Kwa AL, Drusano GL, et al. Population pharmacokinetics of extended-infusion piperacillin\u2013tazobactam in hospitalized patients with nosocomial infections. Antimicrob Agents Chemother. 2012;56:4087\u201394.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR24","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1365-2125.2010.03750.x","volume":"70","author":"JB Bulitta","year":"2010","unstructured":"Bulitta JB, Kinzig M, Jakob V, Holzgrabe U, S\u00f6rgel F, Holford NHG. Nonlinear pharmacokinetics of piperacillin in healthy volunteers\u2014implications for optimal dosage regimens. Br J Clin Pharmacol. 2010;70:682\u201393.","journal-title":"Br J Clin Pharmacol."},{"key":"981_CR25","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.jcf.2015.10.005","volume":"15","author":"K \u00d6brink-Hansen","year":"2016","unstructured":"\u00d6brink-Hansen K, Jensen-Fangel S, Brock B, Hardlei TF, Adelfred A, Nejatbakhsh Y, et al. Piperacillin\/tazobactam continuous infusion at 12G\/1.5G per day in CF patients results in target plasma-concentrations. J Cyst Fibros. 2016;15:e13\u20134.","journal-title":"J Cyst Fibros"},{"key":"981_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/ppul.1950030212","volume":"3","author":"MD Reed","year":"1987","unstructured":"Reed MD, Stern RC, Myers CM, Klinger JD, Yamashita TS, Blumer JL. Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol. 1987;3:101\u20139.","journal-title":"Pediatr Pulmonol."},{"key":"981_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ppul.1950040403","volume":"4","author":"JM McCarty","year":"1988","unstructured":"McCarty JM, Tilden SJ, Black P, Craft JC, Blumer J, Waring W, et al. Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis. Pediatr Pulmonol. 1988;4:201\u20134.","journal-title":"Pediatr Pulmonol."},{"key":"981_CR28","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.clinthera.2005.06.013","volume":"27","author":"JW Mouton","year":"2005","unstructured":"Mouton JW, Punt N, Vinks AA. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin Ther. 2005;27:762\u201372.","journal-title":"Clin Ther."},{"key":"981_CR29","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1128\/AAC.00936-09","volume":"54","author":"JB Bulitta","year":"2010","unstructured":"Bulitta JB, Landersdorfer CB, H\u00fcttner SJ, Drusano GL, Kinzig M, Holzgrabe U, et al. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother. 2010;54:1275\u201382.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/00007691-199408000-00002","volume":"16","author":"AA Vinks","year":"1994","unstructured":"Vinks AA, Touw DJ, Heijerman HG, Danhof M, de Leede GP, Bakker W. Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Ther Drug Monit. 1994;16:341\u20138.","journal-title":"Ther Drug Monit."},{"key":"981_CR31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/jac\/40.1.125","volume":"40","author":"AA Vinks","year":"1997","unstructured":"Vinks AA, Brimicombe RW, Heijerman HG, Bakker W. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother. 1997;40:125\u201333.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2165\/00003088-198815010-00005","volume":"15","author":"A Hedman","year":"1988","unstructured":"Hedman A, Adan-Abdi Y, Alvan G, Strandvik B, Arvidsson A. Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis. Clin Pharmacokinet. 1988;15:57\u201365.","journal-title":"Clin Pharmacokinet."},{"key":"981_CR33","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1128\/AAC.40.5.1091","volume":"40","author":"AA Vinks","year":"1996","unstructured":"Vinks AA, Mouton JW, Touw DJ, Heijerman HG, Danhof M, Bakker W. Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy. Antimicrob Agents Chemother. 1996;40:1091\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR34","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/clpt.1984.187","volume":"36","author":"JS Leeder","year":"1984","unstructured":"Leeder JS, Spino M, Isles AF, Tesoro AM, Gold R, MacLeod SM. Ceftazidime disposition in acute and stable cystic fibrosis. Clin Pharmacol Ther. 1984;36:355\u201362.","journal-title":"Clin Pharmacol Ther."},{"issue":"Suppl A","key":"981_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/jac\/12.suppl_A.289","volume":"12","author":"CM Kercsmar","year":"1983","unstructured":"Kercsmar CM, Stern RC, Reed MD, Myers CM, Murdell D, Blumer JL. Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. J Antimicrob Chemother. 1983;12(Suppl A):289\u201395.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl A","key":"981_CR36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/jac\/12.suppl_A.341","volume":"12","author":"BM Assael","year":"1983","unstructured":"Assael BM, Boccazzi A, Caccamo ML, Giunta A, Marini A, Padoan R, et al. Clinical pharmacology of ceftazidime in paediatrics. J Antimicrob Chemother. 1983;12(Suppl A):341\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"981_CR37","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0022-3476(83)80377-1","volume":"103","author":"R Padoan","year":"1983","unstructured":"Padoan R, Brienza A, Crossignani RM, Lodi G, Giunta A, Assael BM, et al. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis. J Pediatr. 1983;103:320\u20134.","journal-title":"J Pediatr."},{"key":"981_CR38","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1093\/jac\/14.5.521","volume":"14","author":"A Turner","year":"1984","unstructured":"Turner A, Pedler SJ, Carswell F, Spencer GR, Speller DC. Serum and sputum concentrations of ceftazidime in patients with cystic fibrosis. J Antimicrob Chemother. 1984;14:521\u20137.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR39","first-page":"303","volume":"9","author":"N Martini","year":"1984","unstructured":"Martini N, Agostini M, Barlocco G, Bozzini L, Castellani L, Messori A, et al. Serum and sputum concentrations of azlocillin, cefoperazone and ceftazidime in patients with cystic fibrosis. J Clin Hosp Pharm. 1984;9:303\u20139.","journal-title":"J Clin Hosp Pharm."},{"key":"981_CR40","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/ppul.20671","volume":"42","author":"TF Moriarty","year":"2007","unstructured":"Moriarty TF, McElnay JC, Elborn JS, Tunney MM. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection. Pediatr Pulmonol. 2007;42:1008\u201317.","journal-title":"Pediatr Pulmonol."},{"key":"981_CR41","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/jac\/48.2.325","volume":"48","author":"B Byl","year":"2001","unstructured":"Byl B, Baran D, Jacobs F, Herschuelz A, Thys JP. Serum pharmacokinetics and sputum penetration of amikacin 30 mg\/kg once daily and of ceftazidime 200 mg\/kg\/day as a continuous infusion in cystic fibrosis patients. J Antimicrob Chemother. 2001;48:325\u20137.","journal-title":"J Antimicrob Chemother."},{"issue":"Suppl A","key":"981_CR42","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/jac\/12.suppl_A.283","volume":"12","author":"B Strandvik","year":"1983","unstructured":"Strandvik B, Malmborg AS, Alfredson H, Ericsson A. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis. J Antimicrob Chemother. 1983;12(Suppl A):283\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"981_CR43","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/00006454-199312000-00007","volume":"12","author":"PJ Munzenberger","year":"1993","unstructured":"Munzenberger PJ, Hsu JM, Holliday SJ. Relationship of ceftazidime pharmacokinetic indices with therapeutic outcome in patients with cystic fibrosis. Pediatr Infect Dis J. 1993;12:997\u20131001.","journal-title":"Pediatr Infect Dis J."},{"key":"981_CR44","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1592\/phco.19.8.620.31525","volume":"19","author":"JA Bosso","year":"1999","unstructured":"Bosso JA, Bonapace CR, Flume PA, White RL. A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. Pharmacotherapy. 1999;19:620\u20136.","journal-title":"Pharmacotherapy."},{"key":"981_CR45","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1128\/AAC.41.9.2053","volume":"41","author":"M Manduru","year":"1997","unstructured":"Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 1997;41:2053\u20136.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR46","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/PL00008370","volume":"159","author":"I Rappaz","year":"2000","unstructured":"Rappaz I, Decosterd LA, Bille J, Pilet M, B\u00e9laz N, Roulet M. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur J Pediatr. 2000;159:919\u201325.","journal-title":"Eur J Pediatr."},{"key":"981_CR47","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1128\/AAC.00174-09","volume":"53","author":"D Hubert","year":"2009","unstructured":"Hubert D, Le Roux E, Lavrut T, Wallaert B, Scheid P, Manach D, et al. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrob Agents Chemother. 2009;53:3650\u20136.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR48","first-page":"723","volume":"36","author":"WA Prescott","year":"2011","unstructured":"Prescott WA, Gentile AE, Nagel JL, Pettit RS. Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis. P T Peer-Rev J Formul Manag. 2011;36:723\u201363.","journal-title":"P T Peer-Rev J Formul Manag."},{"key":"981_CR49","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jcf.2016.04.002","volume":"15","author":"RZ Thompson","year":"2016","unstructured":"Thompson RZ, Martin CA, Burgess DR, Rutter WC, Burgess DS. Optimizing beta-lactam pharmacodynamics against Pseudomonas aeruginosa in adult cystic fibrosis patients. J Cyst Fibros. 2016;15:660\u20133.","journal-title":"J Cyst Fibros."},{"key":"981_CR50","doi-asserted-by":"crossref","unstructured":"Bensman TJ, Wang J, Jayne J, Fukushima L, Rao AP, D\u2019Argenio DZ, et al. Pharmacokinetic\u2013pharmacodynamic target attainment analyses to determine optimal dosing of ceftazidime\u2013avibactam for the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Antimicrob Agents Chemother. 2017;61.","DOI":"10.1128\/AAC.00988-17"},{"key":"981_CR51","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/j.1875-9114.1993.tb04308.x","volume":"13","author":"BA Hamelin","year":"1993","unstructured":"Hamelin BA, Moore N, Knupp CA, Ruel M, Vall\u00e9e F, LeBel M. Cefepime pharmacokinetics in cystic fibrosis. Pharmacotherapy. 1993;13:465\u201370.","journal-title":"Pharmacotherapy."},{"key":"981_CR52","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1128\/AAC.37.7.1414","volume":"37","author":"CE Huls","year":"1993","unstructured":"Huls CE, Prince RA, Seilheimer DK, Bosso JA. Pharmacokinetics of cefepime in cystic fibrosis patients. Antimicrob Agents Chemother. 1993;37:1414\u20136.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR53","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/jac\/dkl053","volume":"57","author":"EE Han","year":"2006","unstructured":"Han EE, Beringer PM, Falck P, Louie S, Rao P, Shapiro B, et al. Pilot study of continuous infusion cefepime in adult patients with cystic fibrosis. J Antimicrob Chemother. 2006;57:1017\u20139.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR54","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1001\/archpedi.1992.02160190029013","volume":"146","author":"AG Arguedas","year":"1992","unstructured":"Arguedas AG, Stutman HR, Zaleska M, Knupp CA, Marks MI, Nussbaum E. Cefepime. Pharmacokinetics and clinical response in patients with cystic fibrosis. Am J Dis Child 1960. 1992;146:797\u2013802.","journal-title":"Am J Dis Child 1960"},{"key":"981_CR55","doi-asserted-by":"publisher","first-page":"6578","DOI":"10.1128\/AAC.01566-16","volume":"60","author":"ML Monogue","year":"2016","unstructured":"Monogue ML, Pettit RS, Muhlebach M, Cies JJ, Nicolau DP, Kuti JL. Population pharmacokinetics and safety of ceftolozane-tazobactam in adult cystic fibrosis patients admitted with acute pulmonary exacerbation. Antimicrob Agents Chemother. 2016;60:6578\u201384.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR56","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/phar.1681","volume":"36","author":"EB Autry","year":"2016","unstructured":"Autry EB, Rybak JM, Leung NR, Gardner BM, Burgess DR, Anstead MI, et al. Pharmacokinetic and pharmacodynamic analyses of ceftaroline in adults with cystic fibrosis. Pharmacotherapy. 2016;36:13\u20138.","journal-title":"Pharmacotherapy."},{"key":"981_CR57","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/ppul.23827","volume":"52","author":"J Le","year":"2017","unstructured":"Le J, Bradley JS, Hingtgen S, Skochko S, Black N, Jones RN, et al. Pharmacokinetics of single-dose ceftaroline fosamil in children with cystic fibrosis. Pediatr Pulmonol. 2017;52:1424\u201334.","journal-title":"Pediatr Pulmonol."},{"key":"981_CR58","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.jcf.2017.10.010","volume":"17","author":"EE Barsky","year":"2018","unstructured":"Barsky EE, Pereira LM, Sullivan KJ, Wong A, McAdam AJ, Sawicki GS, et al. Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis. J Cyst Fibros. 2018;17:e25-31.","journal-title":"J Cyst Fibros."},{"key":"981_CR59","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s100960050211","volume":"17","author":"BA Christensson","year":"1998","unstructured":"Christensson BA, Ljungberg B, Eriksson L, Nilsson-Ehle I. Pharmacokinetics of meropenem in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 1998;17:873\u20136.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"981_CR60","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000063216","volume":"47","author":"KQ Bui","year":"2001","unstructured":"Bui KQ, Ambrose PG, Nicolau DP, Lapin CD, Nightingale CH, Quintiliani R. Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients. Chemotherapy. 2001;47:153\u20136.","journal-title":"Chemotherapy"},{"key":"981_CR61","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0149-2918(04)90051-3","volume":"26","author":"JL Kuti","year":"2004","unstructured":"Kuti JL, Nightingale CH, Knauft RF, Nicolau DP. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther. 2004;26:493\u2013501.","journal-title":"Clin Ther."},{"key":"981_CR62","first-page":"47","volume":"41","author":"E Delfino","year":"2018","unstructured":"Delfino E, Fucile C, Del Bono V, Marchese A, Marini V, Coppo E, et al. Pharmacokinetics of high-dose extended-infusion meropenem during pulmonary exacerbation in adult cystic fibrosis patients: a case series. New Microbiol. 2018;41:47\u201351.","journal-title":"New Microbiol."},{"key":"981_CR63","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/jac\/dkv289","volume":"71","author":"RS Pettit","year":"2016","unstructured":"Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, et al. Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis. J Antimicrob Chemother. 2016;71:189\u201395.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR64","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.diagmicrobio.2018.01.020","volume":"91","author":"JL Kuti","year":"2018","unstructured":"Kuti JL, Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, et al. Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbations. Diagn Microbiol Infect Dis. 2018;91:294\u20137.","journal-title":"Diagn Microbiol Infect Dis."},{"key":"981_CR65","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1128\/AAC.27.4.583","volume":"27","author":"MD Reed","year":"1985","unstructured":"Reed MD, Stern RC, O\u2019Brien CA, Yamashita TS, Myers CM, Blumer JL. Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis. Antimicrob Agents Chemother. 1985;27:583\u20138.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR66","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1159\/000238979","volume":"39","author":"T Bergan","year":"1993","unstructured":"Bergan T, Michalsen H, Malmborg AS, Pedersen SS, Pressler T, Storr\u00f8sten OT, et al. Pharmacokinetic evaluation of imipenem combined with cilastatin in cystic fibrosis. Chemotherapy. 1993;39:369\u201373.","journal-title":"Chemotherapy"},{"key":"981_CR67","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/jac\/21.4.471","volume":"21","author":"B Strandvik","year":"1988","unstructured":"Strandvik B, Malmborg AS, Bergan T, Michalsen H, Storr\u00f8sten OT, Wretlind B. Imipenem\/cilastatin, an alternative treatment of pseudomonas infection in cystic fibrosis. J Antimicrob Chemother. 1988;21:471\u201380.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR68","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/jac\/16.5.629","volume":"16","author":"SS Pedersen","year":"1985","unstructured":"Pedersen SS, Pressler T, H\u00f8iby N, Bentzon MW, Koch C. Imipenem\/cilastatin treatment of multiresistant Pseudomonas aeruginosa lung infection in cystic fibrosis. J Antimicrob Chemother. 1985;16:629\u201335.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR69","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/jac\/19.1.101","volume":"19","author":"SS Pedersen","year":"1987","unstructured":"Pedersen SS, Pressler T, Jensen T, Rosdahl VT, Bentzon MW, H\u00f8iby N, et al. Combined imipenem\/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Antimicrob Chemother. 1987;19:101\u20137.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR70","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1128\/AAC.01522-06","volume":"51","author":"AA Vinks","year":"2007","unstructured":"Vinks AA, van Rossem RN, Math\u00f4t RAA, Heijerman HGM, Mouton JW. Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using Monte Carlo simulation. Antimicrob Agents Chemother. 2007;51:3049\u201355.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR71","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ppul.1950020506","volume":"2","author":"MD Reed","year":"1986","unstructured":"Reed MD, Aronoff SC, Stern RC, Yamashita TS, Myers CM, Friedhoff LT, et al. Single-dose pharmacokinetics of aztreonam in children with cystic fibrosis. Pediatr Pulmonol. 1986;2:282\u20136.","journal-title":"Pediatr Pulmonol."},{"key":"981_CR72","first-page":"180","volume":"82","author":"JA Bosso","year":"1987","unstructured":"Bosso JA, Black PG, Matsen JM. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. Am J Med. 1987;82:180\u20134.","journal-title":"Am J Med."},{"key":"981_CR73","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/00006454-198803000-00008","volume":"7","author":"JA Bosso","year":"1988","unstructured":"Bosso JA, Black PG. Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis J. 1988;7:171\u20136.","journal-title":"Pediatr Infect Dis J"},{"key":"981_CR74","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/BF01963771","volume":"8","author":"UB Schaad","year":"1989","unstructured":"Schaad UB, Wedgwood-Krucko J, Guenin K, Buehlmann U, Kraemer R. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. Eur J Clin Microbiol Infect Dis. 1989;8:858\u201365.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"981_CR75","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","volume":"11","author":"G D\u00f6ring","year":"2012","unstructured":"D\u00f6ring G, Flume P, Heijerman H, Elborn JS, Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012;11:461\u201379.","journal-title":"J Cyst Fibros"},{"key":"981_CR76","first-page":"379","volume":"23","author":"A Hahn","year":"2018","unstructured":"Hahn A, Jensen C, Fanous H, Chaney H, Sami I, Perez GF, et al. Relationship of pulmonary outcomes, microbiology, and serum antibiotic concentrations in cystic fibrosis patients. J Pediatr Pharmacol Ther. 2018;23:379\u201389.","journal-title":"J Pediatr Pharmacol Ther."},{"key":"981_CR77","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1128\/AAC.01393-12","volume":"57","author":"W Hengzhuang","year":"2013","unstructured":"Hengzhuang W, Ciofu O, Yang L, Wu H, Song Z, Oliver A, et al. High \u03b2-lactamase levels change the pharmacodynamics of \u03b2-lactam antibiotics in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother. 2013;57:196\u2013204.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR78","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/j.1574-6976.2011.00295.x","volume":"35","author":"R Cant\u00f3n","year":"2011","unstructured":"Cant\u00f3n R, Morosini M-I. Emergence and spread of antibiotic resistance following exposure to antibiotics. FEMS Microbiol Rev. 2011;35:977\u201391.","journal-title":"FEMS Microbiol Rev."},{"key":"981_CR79","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0924-8579(02)00027-4","volume":"19","author":"A MacGowan","year":"2002","unstructured":"MacGowan A, Bowker K. Developments in PK\/PD: optimising efficacy and prevention of resistance. A critical review of PK\/PD in in vitro models. Int J Antimicrob Agents. 2002;19:291\u20138.","journal-title":"Int J Antimicrob Agents"},{"key":"981_CR80","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1038\/s41598-019-38984-y","volume":"9","author":"A Hahn","year":"2019","unstructured":"Hahn A, Fanous H, Jensen C, Chaney H, Sami I, Perez GF, et al. Changes in microbiome diversity following beta-lactam antibiotic treatment are associated with therapeutic versus subtherapeutic antibiotic exposure in cystic fibrosis. Sci Rep. 2019;9:2534.","journal-title":"Sci Rep."},{"key":"981_CR81","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/BF01644141","volume":"15","author":"B Grenier","year":"1987","unstructured":"Grenier B, Autret E, Marchand S, Thompson R. Kinetic parameters of amikacin in cystic fibrosis children. Infection. 1987;15:295\u20139.","journal-title":"Infection"},{"key":"981_CR82","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/BF00870991","volume":"31","author":"E Autret","year":"1986","unstructured":"Autret E, Marchand S, Breteau M, Grenier B. Pharmacokinetics of amikacin in cystic fibrosis: a study of bronchial diffusion. Eur J Clin Pharmacol. 1986;31:79\u201383.","journal-title":"Eur J Clin Pharmacol."},{"key":"981_CR83","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.chest.2018.06.002","volume":"154","author":"LT Hong","year":"2018","unstructured":"Hong LT, Liou TG, Deka R, King JB, Stevens V, Young DC. Pharmacokinetics of continuous infusion beta-lactams in the treatment of acute pulmonary exacerbations in adult patients with cystic fibrosis. Chest. 2018;154:1108\u201314.","journal-title":"Chest"},{"key":"981_CR84","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1007\/BF02282885","volume":"155","author":"P Vic","year":"1996","unstructured":"Vic P, Ategbo S, Turck D, Husson MO, Tassin E, Loeuille GA, et al. Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients. Eur J Pediatr. 1996;155:948\u201353.","journal-title":"Eur J Pediatr."},{"key":"981_CR85","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/jac\/39.3.431","volume":"39","author":"F Canis","year":"1997","unstructured":"Canis F, Husson MO, Turck D, Vic P, Launay V, Ategbo S, et al. Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients. J Antimicrob Chemother. 1997;39:431\u20133.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR86","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S0022-3476(82)80663-X","volume":"100","author":"GL Kearns","year":"1982","unstructured":"Kearns GL, Hilman BC, Wilson JT. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. J Pediatr. 1982;100:312\u20138.","journal-title":"J Pediatr."},{"key":"981_CR87","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/jac\/dkt035","volume":"68","author":"S Alghanem","year":"2013","unstructured":"Alghanem S, Paterson I, Touw DJ, Thomson AH. Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis. J Antimicrob Chemother. 2013;68:1338\u201347.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR88","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1164\/ajrccm.160.5.9810080","volume":"160","author":"NR Crowther Labiris","year":"1999","unstructured":"Crowther Labiris NR, Holbrook AM, Chrystyn H, Macleod SM, Newhouse MT. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study. Am J Respir Crit Care Med. 1999;160:1711\u20136.","journal-title":"Am J Respir Crit Care Med."},{"key":"981_CR89","first-page":"262","volume":"2","author":"LA Bauer","year":"1983","unstructured":"Bauer LA, Piecoro JJ, Wilson HD, Blouin RA. Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis. Clin Pharm. 1983;2:262\u20134.","journal-title":"Clin Pharm."},{"key":"981_CR90","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ppul.1950010504","volume":"1","author":"HJ Mann","year":"1985","unstructured":"Mann HJ, Canafax DM, Cipolle RJ, Daniels CE, Zaske DE, Warwick WJ. Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis. Pediatr Pulmonol. 1985;1:238\u201343.","journal-title":"Pediatr Pulmonol."},{"key":"981_CR91","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0022-3476(87)80178-6","volume":"110","author":"L Hendeles","year":"1987","unstructured":"Hendeles L, Iafrate RP, Stillwell PC, Mangos JA. Individualizing gentamicin dosage in patients with cystic fibrosis: limitations to pharmacokinetic approach. J Pediatr. 1987;110:303\u201310.","journal-title":"J Pediatr."},{"key":"981_CR92","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S0022-3476(83)80737-9","volume":"103","author":"NE MacDonald","year":"1983","unstructured":"MacDonald NE, Anas NG, Peterson RG, Schwartz RH, Brooks JG, Powell KR. Renal clearance of gentamicin in cystic fibrosis. J Pediatr. 1983;103:985\u201390.","journal-title":"J Pediatr."},{"key":"981_CR93","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/ppul.22813","volume":"48","author":"DC Young","year":"2013","unstructured":"Young DC, Zobell JT, Stockmann C, Waters CD, Ampofo K, Sherwin CMT, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Pediatr Pulmonol. 2013;48:1047\u201361.","journal-title":"Pediatr Pulmonol."},{"key":"981_CR94","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1128\/AAC.45.9.2502-2509.2001","volume":"45","author":"M Mulheran","year":"2001","unstructured":"Mulheran M, Degg C, Burr S, Morgan DW, Stableforth DE. Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. Antimicrob Agents Chemother. 2001;45:2502\u20139.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR95","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1093\/jac\/dku175","volume":"69","author":"E van Maarseveen","year":"2014","unstructured":"van Maarseveen E, van Buul-Gast M-C, Abdoellakhan R, Gelinck L, Neef C, Touw D. Once-daily dosed gentamicin is more nephrotoxic than once-daily dosed tobramycin in clinically infected patients. J Antimicrob Chemother. 2014;69:2581\u20133.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR96","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40262-013-0036-y","volume":"52","author":"S Hennig","year":"2013","unstructured":"Hennig S, Standing JF, Staatz CE, Thomson AH. Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis. Clin Pharmacokinet. 2013;52:289\u2013301.","journal-title":"Clin Pharmacokinet."},{"key":"981_CR97","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1023\/A:1008633526772","volume":"19","author":"DJ Touw","year":"1997","unstructured":"Touw DJ, Vinks AA, Neef C. Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm. Pharm World Sci PWS. 1997;19:142\u201351.","journal-title":"Pharm World Sci PWS."},{"key":"981_CR98","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/jac\/dkm097","volume":"59","author":"W Lam","year":"2007","unstructured":"Lam W, Tjon J, Seto W, Dekker A, Wong C, Atenafu E, et al. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. J Antimicrob Chemother. 2007;59:1135\u201340.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR99","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jcf.2006.12.007","volume":"6","author":"DJ Touw","year":"2007","unstructured":"Touw DJ, Knox AJ, Smyth A. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. J Cyst Fibros. 2007;6:327\u201333.","journal-title":"J Cyst Fibros."},{"key":"981_CR100","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1378\/chest.88.2.260","volume":"88","author":"AM Horrevorts","year":"1985","unstructured":"Horrevorts AM, Degener JE, Dzoljic-Danilovic G, Michel MF, Kerrebijn KF, Driessen O, et al. Pharmacokinetics of tobramycin in patients with cystic fibrosis. Implications for the dosing interval. Chest. 1985;88:260\u20134.","journal-title":"Chest"},{"key":"981_CR101","first-page":"152","volume":"23","author":"A Arends","year":"2018","unstructured":"Arends A, Pettit R. Safety of extended interval tobramycin in cystic fibrosis patients less an 6 years old. J Pediatr Pharmacol Ther. 2018;23:152\u20138.","journal-title":"J Pediatr Pharmacol Ther."},{"key":"981_CR102","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jac\/dkf168","volume":"50","author":"A Aminimanizani","year":"2002","unstructured":"Aminimanizani A, Beringer PM, Kang J, Tsang L, Jelliffe RW, Shapiro BJ. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. J Antimicrob Chemother. 2002;50:553\u20139.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR103","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1093\/jac\/37.5.1040","volume":"37","author":"BJ Guglielmo","year":"1996","unstructured":"Guglielmo BJ, Quan LA, Stulbarg MS. Pharmacokinetics of once-daily versus thrice daily tobramycin in cystic fibrosis patients. J Antimicrob Chemother. 1996;37:1040\u20132.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR104","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1136\/adc.78.6.536","volume":"78","author":"P Vic","year":"1998","unstructured":"Vic P, Ategbo S, Turck D, Husson MO, Launay V, Loeuille GA, et al. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Arch Dis Child. 1998;78:536\u20139.","journal-title":"Arch Dis Child."},{"key":"981_CR105","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jcf.2015.07.012","volume":"15","author":"AP Prayle","year":"2016","unstructured":"Prayle AP, Jain K, Touw DJ, Koch BCP, Knox AJ, Watson A, et al. The pharmacokinetics and toxicity of morning vs evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: a randomised comparison. J Cyst Fibros. 2016;15:510\u20137.","journal-title":"J Cyst Fibros."},{"key":"981_CR106","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/j.1399-3062.2011.00651.x","volume":"13","author":"KA Walsh","year":"2011","unstructured":"Walsh KA, Davis GA, Hayes D, Kuhn RJ, Weant KA, Flynn JD. Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation. Transpl Infect Dis. 2011;13:616\u201321.","journal-title":"Transpl Infect Dis."},{"key":"981_CR107","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/00007691-199904000-00004","volume":"21","author":"RE Dupuis","year":"1999","unstructured":"Dupuis RE, Sredzienski ES. Tobramycin pharmacokinetics in patients with cystic fibrosis preceding and following lung transplantation. Ther Drug Monit. 1999;21:161\u20135.","journal-title":"Ther Drug Monit."},{"key":"981_CR108","first-page":"239","volume":"21","author":"JT Zobell","year":"2016","unstructured":"Zobell JT, Epps K, Kittell F, Sema C, McDade EJ, Peters SJ, et al. Tobramycin and beta-lactam antibiotic use in cystic fibrosis exacerbations: a pharmacist approach. J Pediatr Pharmacol Ther. 2016;21:239\u201346.","journal-title":"J Pediatr Pharmacol Ther."},{"key":"981_CR109","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1378\/chest.112.5.1208","volume":"112","author":"RD Bates","year":"1997","unstructured":"Bates RD, Nahata MC, Jones JW, McCoy K, Young G, Cox S, et al. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest. 1997;112:1208\u201313.","journal-title":"Chest"},{"key":"981_CR110","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0140-6736(05)17906-9","volume":"365","author":"A Smyth","year":"2005","unstructured":"Smyth A, Tan KH-V, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis\u2014the TOPIC study: a randomised controlled trial. Lancet. 2005;365:573\u20138.","journal-title":"Lancet"},{"key":"981_CR111","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1179\/1973947815Y.0000000077","volume":"28","author":"R Brigg Turner","year":"2016","unstructured":"Brigg Turner R, Elbarbry F, Biondo L. Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis. J Chemother Florence Italy. 2016;28:304\u20137.","journal-title":"J Chemother Florence Italy."},{"key":"981_CR112","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10928-013-9348-7","volume":"41","author":"CMT Sherwin","year":"2014","unstructured":"Sherwin CMT, Zobell JT, Stockmann C, McCrory BE, Wisdom M, Young DC, et al. Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis. J Pharmacokinet Pharmacodyn. 2014;41:71\u20139.","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"981_CR113","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1128\/AAC.44.4.809-813.2000","volume":"44","author":"PM Beringer","year":"2000","unstructured":"Beringer PM, Vinks AA, Jelliffe RW, Shapiro BJ. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob Agents Chemother. 2000;44:809\u201313.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR114","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1093\/jac\/dkz192","volume":"74","author":"SS Alghanem","year":"2019","unstructured":"Alghanem SS, Touw DJ, Thomson AH. Pharmacokinetic\/pharmacodynamic analysis of weight- and height-scaled tobramycin dosage regimens for patients with cystic fibrosis. J Antimicrob Chemother. 2019;74:2311\u20137.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR115","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/00007691-199906000-00004","volume":"21","author":"D Campbell","year":"1999","unstructured":"Campbell D, Thomson AH, Stack B. Population pharmacokinetics of aminoglycoside antibiotics in patients with cystic fibrosis. Ther Drug Monit. 1999;21:281\u20138.","journal-title":"Ther Drug Monit."},{"key":"981_CR116","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1183\/09031936.02.00221602","volume":"19","author":"A Whitehead","year":"2002","unstructured":"Whitehead A, Conway SP, Etherington C, Caldwell NA, Setchfield N, Bogle S. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J. 2002;19:303\u20139.","journal-title":"Eur Respir J."},{"key":"981_CR117","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/jac\/dkl328","volume":"58","author":"O Burkhardt","year":"2006","unstructured":"Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? J Antimicrob Chemother. 2006;58:822\u20139.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR118","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.1128\/AAC.00539-13","volume":"57","author":"JM Butterfield","year":"2013","unstructured":"Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP. Pharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation. Antimicrob Agents Chemother. 2013;57:5175\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR119","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.diagmicrobio.2005.02.011","volume":"52","author":"JW Mouton","year":"2005","unstructured":"Mouton JW, Jacobs N, Tiddens H, Horrevorts AM. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn Microbiol Infect Dis. 2005;52:123\u20137.","journal-title":"Diagn Microbiol Infect Dis."},{"key":"981_CR120","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/ppul.20429","volume":"41","author":"RL Gibson","year":"2006","unstructured":"Gibson RL, Retsch-Bogart GZ, Oermann C, Milla C, Pilewski J, Daines C, et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2006;41:656\u201365.","journal-title":"Pediatr Pulmonol."},{"key":"981_CR121","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jcf.2016.12.003","volume":"16","author":"DP Nichols","year":"2017","unstructured":"Nichols DP, Happoldt CL, Bratcher PE, Caceres SM, Chmiel JF, Malcolm KC, et al. Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis. J Cyst Fibros. 2017;16:358\u201366.","journal-title":"J Cyst Fibros."},{"key":"981_CR122","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1513\/AnnalsATS.201811-774OC","volume":"16","author":"M Klingel","year":"2019","unstructured":"Klingel M, Stanojevic S, Tullis E, Ratjen F, Waters V. Oral azithromycin and response to pulmonary exacerbations treated with intravenous tobramycin in children with cystic fibrosis. Ann Am Thorac Soc. 2019;16:861\u20137.","journal-title":"Ann Am Thorac Soc."},{"key":"981_CR123","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1513\/AnnalsATS.201811-773OC","volume":"16","author":"R Somayaji","year":"2019","unstructured":"Somayaji R, Russell R, Cogen JD, Goss CH, Nick SE, Saavedra MT, et al. Oral azithromycin use and the recovery of lung function from pulmonary exacerbations treated with intravenous tobramycin or colistimethate in adults with cystic fibrosis. Ann Am Thorac Soc. 2019;16:853\u201360.","journal-title":"Ann Am Thorac Soc."},{"key":"981_CR124","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1164\/rccm.201906-1206OC","volume":"201","author":"DP Nichols","year":"2020","unstructured":"Nichols DP, Odem-Davis K, Cogen JD, Goss CH, Ren CL, Skalland M, et al. Pulmonary outcomes associated with long-term azithromycin therapy in cystic fibrosis. Am J Respir Crit Care Med. 2020;201:430\u20137.","journal-title":"Am J Respir Crit Care Med."},{"key":"981_CR125","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s150100050027","volume":"27","author":"K Bartel","year":"1999","unstructured":"Bartel K, Habash T, Lugauer S, B\u00e4rmeier H, B\u00f6wing B, Unsal M, et al. Optimal tobramycin dosage in patients with cystic fibrosis\u2014evidence for predictability based on previous drug monitoring. Infection. 1999;27:268\u201371.","journal-title":"Infection"},{"key":"981_CR126","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1128\/AAC.02654-15","volume":"60","author":"C Bloomfield","year":"2016","unstructured":"Bloomfield C, Staatz CE, Unwin S, Hennig S. Assessing predictive performance of published population pharmacokinetic models of intravenous tobramycin in pediatric patients. Antimicrob Agents Chemother. 2016;60:3407\u201314.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR127","doi-asserted-by":"publisher","first-page":"6698","DOI":"10.1128\/AAC.01131-16","volume":"60","author":"MA Barras","year":"2016","unstructured":"Barras MA, Serisier D, Hennig S, Jess K, Norris RLG. Bayesian estimation of tobramycin exposure in patients with cystic fibrosis. Antimicrob Agents Chemother. 2016;60:6698\u2013702.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR128","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jcf.2006.05.015","volume":"6","author":"KP Coulthard","year":"2007","unstructured":"Coulthard KP, Peckham DG, Conway SP, Smith CA, Bell J, Turnidge J. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis\u2013caution with trough concentrations. J Cyst Fibros. 2007;6:125\u201330.","journal-title":"J Cyst Fibros."},{"key":"981_CR129","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40262-014-0211-9","volume":"54","author":"S Hennig","year":"2015","unstructured":"Hennig S, Holthouse F, Staatz CE. Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis. Clin Pharmacokinet. 2015;54:409\u201321.","journal-title":"Clin Pharmacokinet."},{"key":"981_CR130","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/phar.1762","volume":"36","author":"BA Staubes","year":"2016","unstructured":"Staubes BA, Metzger NL, Walker SD, Peasah SK. Evaluation of a once\/day tobramycin regimen to achieve target concentrations in adult patients with cystic fibrosis. Pharmacotherapy. 2016;36:623\u201330.","journal-title":"Pharmacotherapy."},{"key":"981_CR131","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1128\/AAC.00995-05","volume":"50","author":"M Mulheran","year":"2006","unstructured":"Mulheran M, Hyman-Taylor P, Tan KH-V, Lewis S, Stableforth D, Knox A, et al. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients. Antimicrob Agents Chemother. 2006;50:2293\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"981_CR132","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3109\/00016480903015150","volume":"130","author":"RJ Scheenstra","year":"2010","unstructured":"Scheenstra RJ, Heijerman HGM, Zuur CL, Touw DJ, Rijntjes E. No hearing loss after repeated courses of tobramycin in cystic fibrosis patients. Acta Otolaryngol (Stockh). 2010;130:253\u20138.","journal-title":"Acta Otolaryngol (Stockh)."},{"key":"981_CR133","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3109\/14992027.2010.524253","volume":"50","author":"G Al-Malky","year":"2011","unstructured":"Al-Malky G, Suri R, Dawson SJ, Sirimanna T, Kemp D. Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: a study using extended high-frequency audiometry and distortion product otoacoustic emissions. Int J Audiol. 2011;50:112\u201322.","journal-title":"Int J Audiol."},{"key":"981_CR134","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jcf.2014.07.009","volume":"14","author":"G Al-Malky","year":"2015","unstructured":"Al-Malky G, Dawson SJ, Sirimanna T, Bagkeris E, Suri R. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis. J Cyst Fibros. 2015;14:248\u201354.","journal-title":"J Cyst Fibros."},{"key":"981_CR135","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2165\/00003088-200140110-00002","volume":"40","author":"M Tod","year":"2001","unstructured":"Tod M, Padoin C, Petitjean O. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods? Clin Pharmacokinet. 2001;40:803\u201314.","journal-title":"Clin Pharmacokinet."},{"key":"981_CR136","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 10.0. 2020. https:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed 02 Jul 2020."},{"key":"981_CR137","doi-asserted-by":"crossref","unstructured":"Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev. 2010;3(3):CD002009.","DOI":"10.1002\/14651858.CD002009.pub3"},{"key":"981_CR138","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/BF01644804","volume":"14","author":"SW Bender","year":"1986","unstructured":"Bender SW, Dalhoff A, Shah PM, Strehl R, Posselt HG. Ciprofloxacin pharmacokinetics in patients with cystic fibrosis. Infection. 1986;14:17\u201321.","journal-title":"Infection"},{"key":"981_CR139","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/j.1552-4604.1988.tb03202.x","volume":"28","author":"MD Reed","year":"1988","unstructured":"Reed MD, Stern RC, Myers CM, Yamashita TS, Blumer JL. Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. J Clin Pharmacol. 1988;28:691\u20139.","journal-title":"J Clin Pharmacol."},{"key":"981_CR140","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1128\/AAC.36.11.2512","volume":"36","author":"BA Christensson","year":"1992","unstructured":"Christensson BA, Nilsson-Ehle I, Ljungberg B, Lindblad A, Malmborg AS, Hjelte L, et al. Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother. 1992;36:2512\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR141","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1128\/AAC.30.2.260","volume":"30","author":"M LeBel","year":"1986","unstructured":"LeBel M, Bergeron MG, Vall\u00e9e F, Fiset C, Chass\u00e9 G, Bigonesse P, et al. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother. 1986;30:260\u20136.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR142","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1128\/AAC.31.6.915","volume":"31","author":"RL Davis","year":"1987","unstructured":"Davis RL, Koup JR, Williams-Warren J, Weber A, Heggen L, Stempel D, et al. Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob Agents Chemother. 1987;31:915\u20139.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR143","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1128\/AAC.45.12.3468-3473.2001","volume":"45","author":"MJ Montgomery","year":"2001","unstructured":"Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, et al. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 2001;45:3468\u201373.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR144","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/jac\/24.5.787","volume":"24","author":"HJ Steen","year":"1989","unstructured":"Steen HJ, Scott EM, Stevenson MI, Black AE, Redmond AO, Collier PS. Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbations of pseudomonas infection in cystic fibrosis patients. J Antimicrob Chemother. 1989;24:787\u201395.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR145","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ppul.23638","volume":"52","author":"AN\u00d8 Schultz","year":"2017","unstructured":"Schultz AN\u00d8, H\u00f8iby N, Nielsen XC, Pressler T, Dalhoff K, Duno M, et al. Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients. Pediatr Pulmonol. 2017;52:319\u201323.","journal-title":"Pediatr Pulmonol."},{"key":"981_CR146","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/jac\/20.4.585","volume":"20","author":"T Jensen","year":"1987","unstructured":"Jensen T, Pedersen SS, Nielsen CH, H\u00f8iby N, Koch C. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Antimicrob Chemother. 1987;20:585\u201394.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR147","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/00006454-199701000-00033","volume":"16","author":"TT Rubio","year":"1997","unstructured":"Rubio TT, Miles MV, Lettieri JT, Kuhn RJ, Echols RM, Church DA. Pharmacokinetic disposition of sequential intravenous\/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. Pediatr Infect Dis J. 1997;16:112\u20137 ((discussion 123\u2013126)).","journal-title":"Pediatr Infect Dis J."},{"key":"981_CR148","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1128\/AAC.47.10.3170-3178.2003","volume":"47","author":"S Payen","year":"2003","unstructured":"Payen S, Serreau R, Munck A, Aujard Y, Aigrain Y, Bressolle F, et al. Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections. Antimicrob Agents Chemother. 2003;47:3170\u20138.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR149","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1128\/AAC.40.1.29","volume":"40","author":"HG Schaefer","year":"1996","unstructured":"Schaefer HG, Stass H, Wedgwood J, Hampel B, Fischer C, Kuhlmann J, et al. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. Antimicrob Agents Chemother. 1996;40:29\u201334.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR150","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1177\/0091270003254802","volume":"43","author":"P Rajagopalan","year":"2003","unstructured":"Rajagopalan P, Gastonguay MR. Population pharmacokinetics of ciprofloxacin in pediatric patients. J Clin Pharmacol. 2003;43:698\u2013710.","journal-title":"J Clin Pharmacol."},{"key":"981_CR151","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1592\/phco.30.12.1252","volume":"30","author":"E Guillot","year":"2010","unstructured":"Guillot E, Sermet I, Ferroni A, Chhun S, Pons G, Zahar J-R, et al. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis. Pharmacotherapy. 2010;30:1252\u20138.","journal-title":"Pharmacotherapy."},{"key":"981_CR152","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/j.1552-4604.1986.tb02938.x","volume":"26","author":"J Goldfarb","year":"1986","unstructured":"Goldfarb J, Wormser GP, Inchiosa MA, Guideri G, Diaz M, Gandhi R, et al. Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. J Clin Pharmacol. 1986;26:222\u20136.","journal-title":"J Clin Pharmacol."},{"key":"981_CR153","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/jac\/20.4.575","volume":"20","author":"SS Pedersen","year":"1987","unstructured":"Pedersen SS, Jensen T, Hvidberg EF. Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. J Antimicrob Chemother. 1987;20:575\u201383.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR154","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1128\/AAC.30.4.614","volume":"30","author":"MJ Smith","year":"1986","unstructured":"Smith MJ, White LO, Bowyer H, Willis J, Hodson ME, Batten JC. Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. Antimicrob Agents Chemother. 1986;30:614\u20136.","journal-title":"Antimicrob Agents Chemother."},{"issue":"Suppl 1","key":"981_CR155","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2165\/00003495-198700341-00012","volume":"34","author":"D H\u00f6ffler","year":"1987","unstructured":"H\u00f6ffler D, Koeppe P. Pharmacokinetics of ofloxacin in healthy subjects and patients with impaired renal function. Drugs. 1987;34(Suppl 1):51\u20135.","journal-title":"Drugs."},{"key":"981_CR156","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jcf.2006.01.003","volume":"5","author":"MP Pai","year":"2006","unstructured":"Pai MP, Allen SE, Amsden GW. Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate. J Cyst Fibros. 2006;5:153\u20137.","journal-title":"J Cyst Fibros."},{"key":"981_CR157","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1378\/chest.06-1524","volume":"131","author":"CKK Lee","year":"2007","unstructured":"Lee CKK, Boyle MP, Diener-West M, Brass-Ernst L, Noschese M, Zeitlin PL. Levofloxacin pharmacokinetics in adult cystic fibrosis. Chest. 2007;131:796\u2013802.","journal-title":"Chest"},{"key":"981_CR158","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","volume":"37","author":"A Forrest","year":"1993","unstructured":"Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37:1073\u201381.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR159","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1128\/JCM.43.10.5085-5090.2005","volume":"43","author":"D Hill","year":"2005","unstructured":"Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, et al. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microbiol. 2005;43:5085\u201390.","journal-title":"J Clin Microbiol."},{"key":"981_CR160","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1128\/AAC.00248-09","volume":"54","author":"P King","year":"2010","unstructured":"King P, Lomovskaya O, Griffith DC, Burns JL, Dudley MN. In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob Agents Chemother. 2010;54:143\u20138.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR161","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/jac\/dkg468","volume":"52","author":"J Li","year":"2003","unstructured":"Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother. 2003;52:987\u201392.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR162","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1128\/AAC.01705-13","volume":"58","author":"S Yapa","year":"2014","unstructured":"Yapa S, Li J, Patel K, Wilson JW, Dooley MJ, George J, et al. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother. 2014;58:2570\u20139.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR163","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jcf.2019.08.027","volume":"19","author":"S Magr\u00e9ault","year":"2020","unstructured":"Magr\u00e9ault S, Mankikian J, Marchand S, Diot P, Couet W, Flament T, et al. Pharmacokinetics of colistin after nebulization or intravenous administration of colistin methanesulphonate (Colimycin\u00ae) to cystic fibrosis patients. J Cyst Fibros. 2020;19:421\u20136.","journal-title":"J Cyst Fibros."},{"key":"981_CR164","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1128\/AAC.45.3.781-785.2001","volume":"45","author":"J Li","year":"2001","unstructured":"Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2001;45:781\u20135.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR165","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s40262-017-0561-1","volume":"56","author":"N Gr\u00e9goire","year":"2017","unstructured":"Gr\u00e9goire N, Aranzana-Climent V, Magr\u00e9ault S, Marchand S, Couet W. Clinical pharmacokinetics and pharmacodynamics of colistin. Clin Pharmacokinet. 2017;56:1441\u201360.","journal-title":"Clin Pharmacokinet."},{"key":"981_CR166","first-page":"2311","volume":"68","author":"H He","year":"2013","unstructured":"He H, Li J-C, Nation RL, Jacob J, Chen G, Lee HJ, et al. Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. J Antimicrob Chemother. 2013;68:2311\u20137.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR167","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ijantimicag.2016.08.020","volume":"48","author":"JP Horcajada","year":"2016","unstructured":"Horcajada JP, Sorl\u00ed L, Luque S, Benito N, Segura C, Campillo N, et al. Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate. Int J Antimicrob Agents. 2016;48:725\u20137.","journal-title":"Int J Antimicrob Agents."},{"key":"981_CR168","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1128\/AAC.01797-10","volume":"55","author":"RA Keel","year":"2011","unstructured":"Keel RA, Schaeftlein A, Kloft C, Pope JS, Knauft RF, Muhlebach M, et al. Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrob Agents Chemother. 2011;55:3393\u20138.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR169","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1124\/dmd.106.013755","volume":"35","author":"N Plock","year":"2007","unstructured":"Plock N, Buerger C, Joukhadar C, Kljucar S, Kloft C. Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. Drug Metab Dispos Biol Fate Chem. 2007;35:1816\u201323.","journal-title":"Drug Metab Dispos Biol Fate Chem."},{"key":"981_CR170","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1128\/AAC.48.1.281-284.2004","volume":"48","author":"JA Bosso","year":"2004","unstructured":"Bosso JA, Flume PA, Gray SL. Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 2004;48:281\u20134.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR171","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/jac\/dkh072","volume":"53","author":"D Saralaya","year":"2004","unstructured":"Saralaya D, Peckham DG, Hulme B, Tobin CM, Denton M, Conway S, et al. Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis. J Antimicrob Chemother. 2004;53:325\u20138.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR172","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/ppul.20966","volume":"44","author":"RP Santos","year":"2009","unstructured":"Santos RP, Prestidge CB, Brown ME, Urbancyzk B, Murphey DK, Salvatore CM, et al. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis. Pediatr Pulmonol. 2009;44:148\u201354.","journal-title":"Pediatr Pulmonol."},{"key":"981_CR173","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","volume":"42","author":"CR Rayner","year":"2003","unstructured":"Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 2003;42:1411\u201323.","journal-title":"Clin Pharmacokinet."},{"key":"981_CR174","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/jac\/dkn302","volume":"62","author":"A Molina","year":"2008","unstructured":"Molina A, Del Campo R, M\u00e1iz L, Morosini M-I, Lamas A, Baquero F, et al. High prevalence in cystic fibrosis patients of multiresistant hospital-acquired methicillin-resistant Staphylococcus aureus ST228-SCCmecI capable of biofilm formation. J Antimicrob Chemother. 2008;62:961\u20137.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR175","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1128\/AAC.40.1.186","volume":"40","author":"RA Pleasants","year":"1996","unstructured":"Pleasants RA, Michalets EL, Williams DM, Samuelson WM, Rehm JR, Knowles MR. Pharmacokinetics of vancomycin in adult cystic fibrosis patients. Antimicrob Agents Chemother. 1996;40:186\u201390.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR176","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1002\/phar.1320","volume":"33","author":"C Stockmann","year":"2013","unstructured":"Stockmann C, Sherwin CMT, Zobell JT, Lubsch L, Young DC, Olson J, et al. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis. Pharmacotherapy. 2013;33:1288\u201396.","journal-title":"Pharmacotherapy."},{"key":"981_CR177","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","volume":"43","author":"PA Moise-Broder","year":"2004","unstructured":"Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925\u201342.","journal-title":"Clin Pharmacokinet."},{"key":"981_CR178","first-page":"155","volume":"21","author":"EJ McDade","year":"2016","unstructured":"McDade EJ, Hewlett JL, Moonnumakal SP, Baker CJ. Evaluation of vancomycin dosing in pediatric cystic fibrosis patients. J Pediatr Pharmacol Ther. 2016;21:155\u201361.","journal-title":"J Pediatr Pharmacol Ther."},{"key":"981_CR179","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/jcph.1061","volume":"58","author":"RW Amin","year":"2018","unstructured":"Amin RW, Guttmann RP, Harris QR, Thomas JW. Prediction of vancomycin dose for recommended trough concentrations in pediatric patients with cystic fibrosis. J Clin Pharmacol. 2018;58:662\u20135.","journal-title":"J Clin Pharmacol."},{"key":"981_CR180","doi-asserted-by":"crossref","unstructured":"Zasowski EJ, Murray KP, Trinh TD, Finch NA, Pogue JM, Mynatt RP, et al. Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin. Antimicrob Agents Chemother. 2018;62.","DOI":"10.1128\/AAC.01684-17"},{"key":"981_CR181","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jcph.1323","volume":"59","author":"C Stockmann","year":"2019","unstructured":"Stockmann C, Olson J, Rashid J, Lubsch L, Young DC, Hersh AL, et al. An evaluation of vancomycin area under the curve estimation methods for children treated for acute pulmonary exacerbations of cystic fibrosis due to methicillin-resistant Staphylococcus aureus. J Clin Pharmacol. 2019;59:198\u2013205.","journal-title":"J Clin Pharmacol."},{"key":"981_CR182","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/jpids\/pit076","volume":"3","author":"CA Knoderer","year":"2014","unstructured":"Knoderer CA, Nichols KR, Lyon KC, Veverka MM, Wilson AC. Are elevated vancomycin serum trough concentrations achieved within the first 7 days of therapy associated with acute kidney injury in children? J Pediatr Infect Dis Soc. 2014;3:127\u201331.","journal-title":"J Pediatr Infect Dis Soc."},{"key":"981_CR183","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1093\/jpids\/piu110","volume":"4","author":"J Le","year":"2015","unstructured":"Le J, Ny P, Capparelli E, Lane J, Ngu B, Muus R, et al. Pharmacodynamic characteristics of nephrotoxicity associated with vancomycin use in children. J Pediatr Infect Dis Soc. 2015;4:e109-116.","journal-title":"J Pediatr Infect Dis Soc."},{"key":"981_CR184","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2146\/ajhp150605","volume":"73","author":"SH Durham","year":"2016","unstructured":"Durham SH, Garza KB, Eiland LS. Relationship between vancomycin dosage and serum trough vancomycin concentrations in pediatric patients with cystic fibrosis. Am J Health Syst Pharm. 2016;73:969\u201374.","journal-title":"Am J Health Syst Pharm."},{"key":"981_CR185","first-page":"125","volume":"23","author":"NM Fusco","year":"2018","unstructured":"Fusco NM, Meaney CJ, Wells C, Frederick CA, Prescott WA. Vancomycin versus vancomycin plus rifampin for the treatment of acute pulmonary exacerbations of cystic fibrosis. J Pediatr Pharmacol Ther. 2018;23:125\u201331.","journal-title":"J Pediatr Pharmacol Ther."},{"key":"981_CR186","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1093\/jpids\/pix043","volume":"6","author":"NM Fusco","year":"2017","unstructured":"Fusco NM, Francisconi R, Meaney CJ, Duman D, Frederick CA, Prescott WA. Association of vancomycin trough concentration with response to treatment for acute pulmonary exacerbation of cystic fibrosis. J Pediatr Infect Dis Soc. 2017;6:e103\u20138.","journal-title":"J Pediatr Infect Dis Soc."},{"key":"981_CR187","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1097\/INF.0b013e318286378e","volume":"32","author":"J Le","year":"2013","unstructured":"Le J, Bradley JS, Murray W, Romanowski GL, Tran TT, Nguyen N, et al. Improved vancomycin dosing in children using area-under-the-curve exposure. Pediatr Infect Dis J. 2013;32:e155\u201363.","journal-title":"Pediatr Infect Dis J."},{"key":"981_CR188","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/INF.0000000000002088","volume":"38","author":"NM Fusco","year":"2019","unstructured":"Fusco NM, Prescott WA, Meaney CJ. Pharmacokinetic monitoring of vancomycin in cystic fibrosis: is it time to move past trough concentrations? Pediatr Infect Dis J. 2019;38:258\u201362.","journal-title":"Pediatr Infect Dis J."},{"key":"981_CR189","doi-asserted-by":"crossref","unstructured":"Orazi G, O\u2019Toole GA. Pseudomonas aeruginosa alters staphylococcus aureus sensitivity to vancomycin in a biofilm model of cystic fibrosis infection. mBio. 2017;8.","DOI":"10.1128\/mBio.00873-17"},{"key":"981_CR190","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0022-3476(84)81019-7","volume":"104","author":"MD Reed","year":"1984","unstructured":"Reed MD, Stern RC, Bertino JS, Myers CM, Yamashita TS, Blumer JL. Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. J Pediatr. 1984;104:303\u20137.","journal-title":"J Pediatr."},{"key":"981_CR191","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ppul.23132","volume":"50","author":"JT Zobell","year":"2015","unstructured":"Zobell JT, Epps KL, Young DC, Montague M, Olson J, Ampofo K, et al. Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatr Pulmonol. 2015;50:552\u20139.","journal-title":"Pediatr Pulmonol."},{"key":"981_CR192","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1128\/AAC.05710-11","volume":"56","author":"PM Beringer","year":"2012","unstructured":"Beringer PM, Owens H, Nguyen A, Benitez D, Rao A, D\u2019Argenio DZ. Pharmacokinetics of doxycycline in adults with cystic fibrosis. Antimicrob Agents Chemother. 2012;56:70\u20134.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR193","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1067\/mva.2002.123757","volume":"35","author":"AK Prall","year":"2002","unstructured":"Prall AK, Longo GM, Mayhan WG, Waltke EA, Fleckten B, Thompson RW, et al. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg. 2002;35:923\u20139.","journal-title":"J Vasc Surg."},{"key":"981_CR194","doi-asserted-by":"crossref","unstructured":"Xu X, Abdalla T, Bratcher PE, Jackson PL, Sabbatini G, Wells JM, et al. Doxycycline improves clinical outcomes during cystic fibrosis exacerbations. Eur Respir J. 2017;49.","DOI":"10.1183\/13993003.01102-2016"},{"key":"981_CR195","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.pharmthera.2014.03.003","volume":"143","author":"MJ Parnham","year":"2014","unstructured":"Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther. 2014;143:225\u201345.","journal-title":"Pharmacol Ther."},{"key":"981_CR196","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1183\/09031936.04.00084304","volume":"24","author":"KW Southern","year":"2004","unstructured":"Southern KW, Barker PM. Azithromycin for cystic fibrosis. Eur Respir J. 2004;24:834\u20138.","journal-title":"Eur Respir J."},{"key":"981_CR197","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1128\/AAC.49.12.5013-5017.2005","volume":"49","author":"P Beringer","year":"2005","unstructured":"Beringer P, Huynh KMT, Kriengkauykiat J, Bi L, Hoem N, Louie S, et al. Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. Antimicrob Agents Chemother. 2005;49:5013\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR198","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/01.ftd.0000195617.69721.a5","volume":"28","author":"EB Wilms","year":"2006","unstructured":"Wilms EB, Touw DJ, Heijerman HGM. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis. Ther Drug Monit. 2006;28:219\u201325.","journal-title":"Ther Drug Monit."},{"key":"981_CR199","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00044011-200121050-00005","volume":"21","author":"M Cipolli","year":"2001","unstructured":"Cipolli M, Cazzola G, Novelli A, Cassetta MI, Fallani S, Mazzei T. Azithromycin concentrations in serum and bronchial secretions of patients with cystic fibrosis. Clin Drug Investig. 2001;21:353\u201360.","journal-title":"Clin Drug Investig."},{"key":"981_CR200","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.rmed.2008.03.009","volume":"102","author":"G Steinkamp","year":"2008","unstructured":"Steinkamp G, Schmitt-Grohe S, D\u00f6ring G, Staab D, Pfr\u00fcnder D, Beck G, et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir Med. 2008;102:1643\u201353.","journal-title":"Respir Med."},{"key":"981_CR201","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jcf.2007.05.005","volume":"7","author":"EB Wilms","year":"2008","unstructured":"Wilms EB, Touw DJ, Heijerman HGM. Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients. J Cyst Fibros. 2008;7:79\u201384.","journal-title":"J Cyst Fibros."},{"key":"981_CR202","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1155\/2004\/747841","volume":"11","author":"U Baumann","year":"2004","unstructured":"Baumann U, King M, App EM, Tai S, K\u00f6nig A, Fischer JJ, et al. Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties. Can Respir J. 2004;11:151\u20135.","journal-title":"Can Respir J."},{"key":"981_CR203","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/ppul.21620","volume":"47","author":"EB Wilms","year":"2012","unstructured":"Wilms EB, Touw DJ, Heijerman HGM, van der Ent CK. Azithromycin maintenance therapy in patients with cystic fibrosis: a dose advice based on a review of pharmacokinetics, efficacy, and side effects. Pediatr Pulmonol. 2012;47:658\u201365.","journal-title":"Pediatr Pulmonol."},{"key":"981_CR204","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1136\/thorax.57.3.212","volume":"57","author":"J Wolter","year":"2002","unstructured":"Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002;57:212\u20136.","journal-title":"Thorax"},{"key":"981_CR205","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S0140-6736(02)11081-6","volume":"360","author":"A Equi","year":"2002","unstructured":"Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet Lond Engl. 2002;360:978\u201384.","journal-title":"Lancet Lond Engl."},{"key":"981_CR206","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","volume":"290","author":"L Saiman","year":"2003","unstructured":"Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290:1749\u201356.","journal-title":"JAMA"},{"key":"981_CR207","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1183\/09031936.00163306","volume":"30","author":"J McCormack","year":"2007","unstructured":"McCormack J, Bell S, Senini S, Walmsley K, Patel K, Wainwright C, et al. Daily versus weekly azithromycin in cystic fibrosis patients. Eur Respir J. 2007;30:487\u201395.","journal-title":"Eur Respir J."},{"key":"981_CR208","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/01.inf.0000148927.48680.fc","volume":"24","author":"RF Jacobs","year":"2005","unstructured":"Jacobs RF, Maples HD, Aranda JV, Espinoza GM, Knirsch C, Chandra R, et al. Pharmacokinetics of intravenously administered azithromycin in pediatric patients. Pediatr Infect Dis J. 2005;24:34\u20139.","journal-title":"Pediatr Infect Dis J."},{"key":"981_CR209","doi-asserted-by":"publisher","first-page":"00686","DOI":"10.1128\/AAC.00686-18","volume":"62","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Liu S-P, Xu B-P, Shi Z-R, Wang K, Yang J-B, et al. Population pharmacokinetics and dosing optimization of azithromycin in children with community-acquired pneumonia. Antimicrob Agents Chemother. 2018;62:00686\u2013718.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR210","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1128\/AAC.43.12.2877","volume":"43","author":"RM Shawar","year":"1999","unstructured":"Shawar RM, MacLeod DL, Garber RL, Burns JL, Stapp JR, Clausen CR, et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 1999;43:2877\u201380.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR211","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1164\/rccm.200712-1804OC","volume":"178","author":"KS McCoy","year":"2008","unstructured":"McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:921\u20138.","journal-title":"Am J Respir Crit Care Med."},{"key":"981_CR212","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1378\/chest.08-1421","volume":"135","author":"GZ Retsch-Bogart","year":"2009","unstructured":"Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009;135:1223\u201332.","journal-title":"Chest"},{"key":"981_CR213","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1093\/jac\/dkr303","volume":"66","author":"CM Oermann","year":"2011","unstructured":"Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, McKevitt M, Montgomery AB. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). J Antimicrob Chemother. 2011;66:2398\u2013404.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR214","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jcf.2011.02.007","volume":"10","author":"CE Wainwright","year":"2011","unstructured":"Wainwright CE, Quittner AL, Geller DE, Nakamura C, Wooldridge JL, Gibson RL, et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. J Cyst Fibros. 2011;10:234\u201342.","journal-title":"J Cyst Fibros"},{"key":"981_CR215","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jcf.2014.06.003","volume":"14","author":"HA Tiddens","year":"2015","unstructured":"Tiddens HA, De Boeck K, Clancy JP, Fayon M, Arets HG, Bresnik M, Derchak A, Lewis SA, Oermann CM, et al. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: the ALPINE study. J Cyst Fibros. 2015;14:111\u20139.","journal-title":"J Cyst Fibros"},{"key":"981_CR216","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jcf.2012.07.006","volume":"12","author":"BM Assael","year":"2013","unstructured":"Assael BM, Pressler T, Bilton D, Fayon M, Fischer R, Chiron R, et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros. 2013;12:130\u201340.","journal-title":"J Cyst Fibros."},{"key":"981_CR217","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1128\/AAC.00872-08","volume":"53","author":"OO Okusanya","year":"2009","unstructured":"Okusanya OO, Bhavnani SM, Hammel J, Minic P, Dupont LJ, Forrest A, et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother. 2009;53:3847\u201354.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR218","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1128\/AAC.02421-13","volume":"58","author":"OO Okusanya","year":"2014","unstructured":"Okusanya OO, Bhavnani SM, Hammel JP, Forrest A, Bulik CC, Ambrose PG, et al. Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies. Antimicrob Agents Chemother. 2014;58:5005\u201315.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR219","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/ppul.20594","volume":"42","author":"DE Geller","year":"2007","unstructured":"Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol. 2007;42:307\u201313.","journal-title":"Pediatr Pulmonol."},{"key":"981_CR220","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jcf.2009.07.001","volume":"8","author":"D Hubert","year":"2009","unstructured":"Hubert D, Leroy S, Nove-Josserand R, Murris-Espin M, Mely L, Dominique S, et al. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. J Cyst Fibros. 2009;8:332\u20137.","journal-title":"J Cyst Fibros."},{"key":"981_CR221","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.pupt.2012.12.002","volume":"26","author":"M Govoni","year":"2013","unstructured":"Govoni M, Poli G, Acerbi D, Santoro D, Cicirello H, Annoni O, et al. Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg\/4 ml administered by PARI eFlow\u00ae rapid and PARI LC Plus\u00ae nebulisers in cystic fibrosis patients. Pulm Pharmacol Ther. 2013;26:249\u201355.","journal-title":"Pulm Pharmacol Ther."},{"key":"981_CR222","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/j.1552-4604.1994.tb03995.x","volume":"34","author":"GF Cooney","year":"1994","unstructured":"Cooney GF, Lum BL, Tomaselli M, Fiel SB. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharmacol. 1994;34:255\u20139.","journal-title":"J Clin Pharmacol."},{"key":"981_CR223","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1378\/chest.122.1.219","volume":"122","author":"DE Geller","year":"2002","unstructured":"Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002;122:219\u201326.","journal-title":"Chest"},{"key":"981_CR224","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1128\/AAC.41.1.184","volume":"41","author":"DJ Touw","year":"1997","unstructured":"Touw DJ, Jacobs FA, Brimicombe RW, Heijerman HG, Bakker W, Briemer DD. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 1997;41:184\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR225","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1016\/j.xphs.2017.06.010","volume":"106","author":"X Wang","year":"2017","unstructured":"Wang X, Koehne-Voss S, Anumolu SS, Yu J. Population pharmacokinetics of tobramycin inhalation solution in pediatric patients with cystic fibrosis. J Pharm Sci. 2017;106:3402\u20139.","journal-title":"J Pharm Sci."},{"key":"981_CR226","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1111\/bcp.13988","volume":"85","author":"AJ van Velzen","year":"2019","unstructured":"van Velzen AJ, Uges JWF, Heijerman HGM, Arets BGM, Nuijsink M, van der Wiel-Kooij EC, et al. Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: a randomized, crossover study. Br J Clin Pharmacol. 2019;85:1984\u201393.","journal-title":"Br J Clin Pharmacol."},{"key":"981_CR227","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1038\/psp.2013.76","volume":"3","author":"L Ting","year":"2014","unstructured":"Ting L, Aksenov S, Bhansali SG, Ramakrishna R, Tang P, Geller DE. Population pharmacokinetics of inhaled tobramycin powder in cystic fibrosis patients. CPT Pharmacometr Syst Pharmacol. 2014;3:e99.","journal-title":"CPT Pharmacometr Syst Pharmacol."},{"key":"981_CR228","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/jac\/dkv399","volume":"71","author":"S van Koningsbruggen-Rietschel","year":"2016","unstructured":"van Koningsbruggen-Rietschel S, Heuer HE, Merkel N, Posselt HG, Staab D, Sieder C, et al. Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients. J Antimicrob Chemother. 2016;71:711\u20137.","journal-title":"J Antimicrob Chemother."},{"issue":"Suppl 5","key":"981_CR229","first-page":"141","volume":"58","author":"R Dopfer","year":"2007","unstructured":"Dopfer R, Brand P, M\u00fcllinger B, Hunger T, H\u00e4ussermann S, Meyer T, et al. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods. J Physiol Pharmacol. 2007;58(Suppl 5):141\u201354.","journal-title":"J Physiol Pharmacol."},{"key":"981_CR230","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1164\/rccm.200208-855OC","volume":"167","author":"RL Gibson","year":"2003","unstructured":"Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med. 2003;167:841\u20139.","journal-title":"Am J Respir Crit Care Med."},{"key":"981_CR231","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1093\/jac\/dku239","volume":"69","author":"MC Berkhout","year":"2014","unstructured":"Berkhout MC, van Velzen AJ, Touw DJ, de Kok BM, Fokkens WJ, Heijerman HGM. Systemic absorption of nasally administered tobramycin and colistin in patients with cystic fibrosis. J Antimicrob Chemother. 2014;69:3112\u20135.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR232","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jcf.2010.08.019","volume":"10","author":"W Lenney","year":"2011","unstructured":"Lenney W, Edenborough F, Kho P, Kovarik JM. Lung deposition of inhaled tobramycin with eFlow rapid\/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. J Cyst Fibros. 2011;10:9\u201314.","journal-title":"J Cyst Fibros."},{"key":"981_CR233","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1183\/09031936.01.99086801","volume":"18","author":"PF Dequin","year":"2001","unstructured":"Dequin PF, Faurisson F, Lemari\u00e9 E, Delatour F, Marchand S, Valat C, et al. Urinary excretion reflects lung deposition of aminoglycoside aerosols in cystic fibrosis. Eur Respir J. 2001;18:316\u201322.","journal-title":"Eur Respir J."},{"key":"981_CR234","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jcf.2014.04.006","volume":"13","author":"D Sands","year":"2014","unstructured":"Sands D, Sapiejka E, G\u0105szczyk G, Mazurek H, T100 Study Group. Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS. J Cyst Fibros. 2014;13:653\u201360.","journal-title":"J Cyst Fibros"},{"key":"981_CR235","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1164\/ajrccm\/136.6.1445","volume":"136","author":"JS Ilowite","year":"1987","unstructured":"Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis. 1987;136:1445\u20139.","journal-title":"Am Rev Respir Dis."},{"issue":"Suppl 1","key":"981_CR236","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2165\/00148581-200709001-00002","volume":"9","author":"G Poli","year":"2007","unstructured":"Poli G, Acerbi D, Pennini R, Soliani Raschini A, Corrado ME, Eichler HG, et al. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi. Paediatr Drugs. 2007;9(Suppl 1):3\u20139.","journal-title":"Paediatr Drugs."},{"key":"981_CR237","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1378\/chest.123.1.28","volume":"123","author":"DE Geller","year":"2003","unstructured":"Geller DE, Rosenfeld M, Waltz DA, Wilmott RW, AeroDose TOBI Study Group. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest. 2003;123:28\u201336.","journal-title":"Chest"},{"key":"981_CR238","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/ppul.1950170511","volume":"17","author":"A Weber","year":"1994","unstructured":"Weber A, Smith A, Williams-Warren J, Ramsey B, Covert DS. Nebulizer delivery of tobramycin to the lower respiratory tract. Pediatr Pulmonol. 1994;17:331\u20139.","journal-title":"Pediatr Pulmonol."},{"key":"981_CR239","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1378\/chest.111.4.955","volume":"111","author":"J Eisenberg","year":"1997","unstructured":"Eisenberg J, Pepe M, Williams-Warren J, Vasiliev M, Montgomery AB, Smith AL, Aerosolized Tobramycin Study Group, et al. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Chest. 1997;111:955\u201362.","journal-title":"Chest"},{"issue":"Suppl 1","key":"981_CR240","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2165\/00148581-200709001-00003","volume":"9","author":"G Lenoir","year":"2007","unstructured":"Lenoir G, Antypkin YG, Miano A, Moretti P, Zanda M, Varoli G, et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatr Drugs. 2007;9(Suppl 1):11\u201320.","journal-title":"Paediatr Drugs."},{"key":"981_CR241","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jcf.2015.01.002","volume":"14","author":"AJ van Velzen","year":"2015","unstructured":"van Velzen AJ, Uges JWF, Le Brun PPH, Shahbabai P, Touw DJ, Heijerman HGM. The influence of breathing mode on tobramycin serum levels using the I-neb AAD system in adults with cystic fibrosis. J Cyst Fibros. 2015;14:748\u201354.","journal-title":"J Cyst Fibros."},{"key":"981_CR242","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1089\/jamp.2015.1259","volume":"29","author":"AJ van Velzen","year":"2016","unstructured":"van Velzen AJ, Bos AC, Touw DJ, Tiddens HA, Heijerman HGM, Janssens HM. Pharmacokinetics and tolerability of once daily double dose tobramycin inhalation in cystic fibrosis using controlled and conventional nebulization. J Aerosol Med Pulm Drug Deliv. 2016;29:273\u201380.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"981_CR243","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ejpb.2007.05.005","volume":"68","author":"G Pilcer","year":"2008","unstructured":"Pilcer G, Goole J, Van Gansbeke B, Blocklet D, Knoop C, Vanderbist F, et al. Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients. Eur J Pharm Biopharm. 2008;68:413\u201321.","journal-title":"Eur J Pharm Biopharm."},{"key":"981_CR244","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/jamp.2011.0942","volume":"26","author":"J Ruddy","year":"2013","unstructured":"Ruddy J, Emerson J, Moss R, Genatossio A, McNamara S, Burns JL, et al. Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin. J Aerosol Med Pulm Drug Deliv. 2013;26:69\u201375.","journal-title":"J Aerosol Med Pulm Drug Deliv."},{"key":"981_CR245","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/jamp.2013.1055","volume":"27","author":"M Al-Aloul","year":"2014","unstructured":"Al-Aloul M, Nazareth D, Walshaw M. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations. J Aerosol Med Pulm Drug Deliv. 2014;27:299\u2013305.","journal-title":"J Aerosol Med Pulm Drug Deliv."},{"key":"981_CR246","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.clinthera.2013.08.003","volume":"35","author":"H Stass","year":"2013","unstructured":"Stass H, Weimann B, Nagelschmitz J, Rolinck-Werninghaus C, Staab D. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. Clin Ther. 2013;35:1571\u201381.","journal-title":"Clin Ther."},{"key":"981_CR247","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1089\/jamp.2013.1056","volume":"28","author":"H Stass","year":"2015","unstructured":"Stass H, Delesen H, Nagelschmitz J, Staab D. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. J Aerosol Med Pulm Drug Deliv. 2015;28:106\u201315.","journal-title":"J Aerosol Med Pulm Drug Deliv."},{"key":"981_CR248","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/jac\/dki461","volume":"57","author":"F Ratjen","year":"2006","unstructured":"Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother. 2006;57:306\u201311.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR249","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/jac\/dkl169","volume":"58","author":"J Li","year":"2006","unstructured":"Li J, Nation RL. Comment on: pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother. 2006;58:222\u20133 ((author reply 223)).","journal-title":"J Antimicrob Chemother"},{"key":"981_CR250","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1128\/AAC.06486-11","volume":"56","author":"W Hengzhuang","year":"2012","unstructured":"Hengzhuang W, Wu H, Ciofu O, Song Z, H\u00f8iby N. In vivo pharmacokinetics\/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother. 2012;56:2683\u201390.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR251","first-page":"3291","volume":"70","author":"S-E Cheah","year":"2015","unstructured":"Cheah S-E, Wang J, Nguyen VTT, Turnidge JD, Li J, Nation RL. New pharmacokinetic\/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother. 2015;70:3291\u20137.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR252","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.1128\/AAC.00126-11","volume":"55","author":"W Hengzhuang","year":"2011","unstructured":"Hengzhuang W, Wu H, Ciofu O, Song Z, H\u00f8iby N. Pharmacokinetics\/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother. 2011;55:4469\u201374.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR253","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/nature03912","volume":"436","author":"LR Hoffman","year":"2005","unstructured":"Hoffman LR, D\u2019Argenio DA, MacCoss MJ, Zhang Z, Jones RA, Miller SI. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature. 2005;436:1171.","journal-title":"Nature"},{"key":"981_CR254","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1128\/AAC.48.4.1175-1187.2004","volume":"48","author":"N Bagge","year":"2004","unstructured":"Bagge N, Schuster M, Hentzer M, Ciofu O, Givskov M, Greenberg EP, et al. Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and \u03b2-lactamase and alginate production. Antimicrob Agents Chemother. 2004;48:1175\u201387.","journal-title":"Antimicrob Agents Chemother."},{"key":"981_CR255","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/jac\/36.4.743","volume":"36","author":"A Takahashi","year":"1995","unstructured":"Takahashi A, Yomoda S, Ushijima Y, Kobayashi I, Inoue M. Ofloxacin, norfloxacin and ceftazidime increase the production of alginate and promote the formation of biofilm of Pscudomonas aeruginosa in vitro. J Antimicrob Chemother. 1995;36:743\u20135.","journal-title":"J Antimicrob Chemother."},{"key":"981_CR256","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/BF02914541","volume":"9","author":"M Spino","year":"1991","unstructured":"Spino M. Pharmacokinetics of drugs in cystic fibrosis. Clin Rev Allergy. 1991;9:169.","journal-title":"Clin Rev Allergy."},{"key":"981_CR257","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2165\/00003088-198713040-00002","volume":"13","author":"R de Groot","year":"1987","unstructured":"de Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clin Pharmacokinet. 1987;13:228\u201353.","journal-title":"Clin Pharmacokinet."},{"key":"981_CR258","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/1469-0691.12651","volume":"20","author":"MD Maci\u00e0","year":"2014","unstructured":"Maci\u00e0 MD, Rojo-Molinero E, Oliver A. Antimicrobial susceptibility testing in biofilm-growing bacteria. Clin Microbiol Infect. 2014;20:981\u201390.","journal-title":"Clin Microbiol Infect"},{"key":"981_CR259","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1183\/09031936.95.08091594","volume":"8","author":"DJ Touw","year":"1995","unstructured":"Touw DJ, Brimicombe RW, Hodson ME, Heijerman HG, Bakker W. Inhalation of antibiotics in cystic fibrosis. Eur Respir J. 1995;8:1594\u2013604.","journal-title":"Eur Respir J."},{"key":"981_CR260","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1136\/thx.38.12.881","volume":"38","author":"SP Newman","year":"1983","unstructured":"Newman SP, Clarke SW. Therapeutic aerosols 1\u2014physical and practical considerations. Thorax. 1983;38:881\u20136.","journal-title":"Thorax"},{"key":"981_CR261","first-page":"297","volume":"86","author":"LW Matthews","year":"1967","unstructured":"Matthews LW, Doershuk CF. Inhalation therapy and postural drainage for the treatment of cystic fibrosis. Bibl Paediatr. 1967;86:297\u2013314.","journal-title":"Bibl Paediatr."},{"key":"981_CR262","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/QCO.0000000000000217","volume":"28","author":"KM Langan","year":"2015","unstructured":"Langan KM, Kotsimbos T, Peleg AY. Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis. Curr Opin Infect Dis. 2015;28:547\u201356.","journal-title":"Curr Opin Infect Dis."},{"key":"981_CR263","doi-asserted-by":"crossref","unstructured":"Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2017;(4):CD004197.","DOI":"10.1002\/14651858.CD004197.pub5"},{"key":"981_CR264","doi-asserted-by":"crossref","unstructured":"Smith S, Rowbotham NJ, Charbek E. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database Syst Rev. 2018;(10):CD008319.","DOI":"10.1002\/14651858.CD008319.pub3"},{"key":"981_CR265","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1741-7015-9-32","volume":"9","author":"N H\u00f8iby","year":"2011","unstructured":"H\u00f8iby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 2011;9:32.","journal-title":"BMC Med."},{"key":"981_CR266","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40262-018-0678-x","volume":"58","author":"JB Bulitta","year":"2019","unstructured":"Bulitta JB, Jiao Y, Drescher SK, Oliver A, Louie A, Moya B, et al. Four decades of \u03b2-lactam antibiotic pharmacokinetics in cystic fibrosis. Clin Pharmacokinet. 2019;58:143\u201356.","journal-title":"Clin Pharmacokinet."},{"key":"981_CR267","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1146\/annurev-pharmtox-010814-124712","volume":"55","author":"DJ Dwyer","year":"2015","unstructured":"Dwyer DJ, Collins JJ, Walker GC. Unraveling the physiological complexities of antibiotic lethality. Annu Rev Pharmacol Toxicol. 2015;55:313\u201332.","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"981_CR268","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40168-017-0265-7","volume":"5","author":"AA Heirali","year":"2017","unstructured":"Heirali AA, Workentine ML, Acosta N, Poonja A, Storey DG, Somayaji R, et al. The effects of inhaled aztreonam on the cystic fibrosis lung microbiome. Microbiome. 2017;5:51.","journal-title":"Microbiome."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00981-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00981-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00981-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T13:25:57Z","timestamp":1698585957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00981-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,24]]},"references-count":268,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["981"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00981-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,24]]},"assertion":[{"value":"20 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Authors report no conflict interest\/competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}